2019-nCoV Spike protein RBD (N501Y) from MyBioSource.com

Supplier Page

Supplier Page from
MyBioSource.com for
2019-nCoV Spike protein RBD (N501Y)

Get Pricing

Description

Recombinant 2019-nCoV Spike protein S1 subunit, RBD (N501Y) (319-541) was expressed in CHO cells using a C-terminal his tag.

Recombinant 2019-nCoV Spike protein S1 subunit, RBD (N501Y) (319-541) was expressed in CHO cells using a C-terminal his tag. The gene accession number is MN908947

The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein recognizes the host ACE2 receptor and is a major determinant of viral entry and neutralization (1). SARS-CoV-2 variant, B.1.1.7 lineage, reported from the United Kingdom possess mutation N501Y at one of the six major contact residues in the receptor-binding domain involved in ACE2 binding. MD studies indicate that the mutant N501Y might increase the stability of the RBD domain with the ACE2 protein thereby resulting in higher virulence compared to the wild type strain (2). As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (3)